uniQure (QURE) Finished Goods (2022 - 2023)
uniQure (QURE) posted quarterly Finished Goods of $758000.0 for Q4 2023, down 48.29% year-over-year from $1.5 million in Q4 2022, and down 53.53% quarter-over-quarter from $1.6 million in Q3 2023.
Powered by 
Analysis
uniQure (QURE) Finished Goods (2022 - 2023) Analysis & Trends
uniQure's Finished Goods history runs 2 years deep, the most recent figure standing at $758000.0 for Q4 2023.
- In Q4 2023, Finished Goods fell 48.29% year-over-year to $758000.0; the TTM figure through Dec 2023 stood at $758000.0 (down 48.29% YoY), while the FY2023 annual figure was $758000.0, down 48.29% from the prior year.
- Finished Goods for Q4 2023 stood at $758000.0, down from $1.6 million in the prior quarter.
- The five-year high for Finished Goods was $1.6 million in Q3 2023, with the low at $140000.0 in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 758,000.00 |
| Sep 30, 2023 | 1.63 Mn |
| Jun 30, 2023 | 140,000.00 |
| Dec 31, 2022 | 1.47 Mn |
| Sep 30, 2022 | 450,000.00 |